Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research

Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC

Authors: Jin Li, Tingyuan Yan, Xiang Wu, Xueping Ke, Xin Li, Yumin Zhu, Jianrong Yang, Zhongwu Li

Published in: BMC Cancer | Issue 1/2021

Abstract

Objectives

Forkhead box D1, the core transcription factor member of FOX family, has gradually seen as a key cancerous regulatory. However, its expression and carcinogenicity in head and neck squamous cell carcinoma (HNSCC) have not been reported yet. This study was to investigate its expression pattern, clinicopathological significance and biological roles in HNSCC.

Methods

HNSCC data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) was used to indicate the detailed expression pattern and outcome association of FOXD1, while Western Blot assay to detect FOXD1 level in a panel of HNSCC cell lines as well as immunocytochemistry to explore FOXD1 protein abundance and sublocation. Series of siRNA-mediated FOXD1 knock-down experiments to assess the proliferation, migration, invasion and anti- apoptosis ability after FOXD1 down-regulation. Bioinformatic analysis to find out which biological function and cancer-related pathways of FOXD1 associated genes involved in.

Results

FOXD1 mRNA was significantly overexpressed in TCGA-HNSCC, GSE6631, GSE12452, GSE25099 and GSE30784. Besides, IHC results shown that nuclear location FOXD1 protein was significantly higher in primary HNSCC specimens from cohort involved in this study. Also, FOXD1 abundance was significantly correlated with cervical node metastasis and poor over-all/disease-free survival after combination analysis with patient pathological information. siRNA-mediated FOXD1 knock-down significantly inhibited cell proliferation, migration and invasion and induced apoptosis in HNSCC cells. Further analysis of GSEA, GO and KEGG showed that FOXD1 expression was significantly associated with oncological function and cancer-related pathways.

Conclusions

Taken together, our study implies that the potential oncogene, FOXD1, facilitates oncological behavior who can be identified as a brand-new HNSCC biomarker with diagnostic and prognostic significance.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Ca-Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25(5):1495–500. https://doi.org/10.3892/ijo.25.5.1495.CrossRefPubMed

Gao YF, Zhu T, Mao XY, Mao CX, Li L, Yin JY, et al. Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells. Oncol Rep. 2017;37(2):1196–202. https://doi.org/10.3892/or.2017.5344.CrossRefPubMed

Pan F, Li M, Chen W. FOXD1 predicts prognosis of colorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway. Am J Transl Res. 2018;10(5):1522–30.PubMedPubMedCentral

Cheng P, Wang J, Waghmare I, Sartini S, Coviello V, Zhang Z, et al. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and Tumorigenicity of mesenchymal glioma stem cells. Cancer Res. 2016;76(24):7219–30. https://doi.org/10.1158/0008-5472.CAN-15-2860.CrossRefPubMedPubMedCentral

Wu H, Larribere L, Sun Q, Novak D, Sachindra S, Granados K, et al. Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation. Int J Cancer. 2018;143(11):2962–72. https://doi.org/10.1002/ijc.31799.CrossRefPubMed

Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019;10(3):178. https://doi.org/10.1038/s41419-019-1431-6.CrossRefPubMedPubMedCentral

10.

Koga M, Matsuda M, Kawamura T, Sogo T, Shigeno A, Nishida E, et al. Foxd1 is a mediator and indicator of the cell reprogramming process. Nat Commun. 2014;5(1):3197. https://doi.org/10.1038/ncomms4197.CrossRefPubMed

11.

Zhao YF, Zhao JY, Yue H, Hu KS, Shen H, Guo ZG, et al. FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochem Biophys Res Commun. 2015;456(1):232–7. https://doi.org/10.1016/j.bbrc.2014.11.064.CrossRefPubMed

12.

Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, et al. The hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol. 2015;9(6):1091–105. https://doi.org/10.1016/j.molonc.2015.01.007.CrossRefPubMedPubMedCentral

13.

Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7. https://doi.org/10.1089/omi.2011.0118.CrossRefPubMedPubMedCentral

14.

Li J, Li Z, Wu Y, Wang Y, Wang D, Zhang W, et al. The hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma. Cell Death Dis. 2019;10(8):603. https://doi.org/10.1038/s41419-019-1838-0.CrossRefPubMedPubMedCentral

15.

Nakayama S, Soejima K, Yasuda H, Yoda S, Satomi R, Ikemura S, et al. FOXD1 expression is associated with poor prognosis in non-small cell lung Cancer. Anticancer Res. 2015;35(1):261–8.PubMed

16.

Li Z, Yan T, Wu X, Zhang W, Li J, Wang L, et al. Increased expression of FOXD1 is associated with cervical node metastasis and unfavorable prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2020;49(10):1030–6. https://doi.org/10.1111/jop.13098.CrossRefPubMed

17.

Jin Y, Liang Z, Lou H. The Emerging Roles of Fox Family Transcription Factors in Chromosome Replication, Organization, and Genome Stability. Cells. 2020;9(1). https://doi.org/10.3390/cells9010258.

18.

Gong Z, Yu J, Yang S, Lai PBS, Chen GG. FOX transcription factor family in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 1874;2020(1):188376. https://doi.org/10.1016/j.bbcan.2020.188376.CrossRef

19.

Li CH, Chang YC, Hsiao M, Liang SM. FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness. Cancers (Basel). 2019;11(12). https://doi.org/10.3390/cancers11121897.

20.

Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82. https://doi.org/10.1038/nrc.2018.11.CrossRefPubMed

21.

Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–83. https://doi.org/10.1038/s41571-019-0227-z.CrossRefPubMed

22.

Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. Asia Pac J Clin Oncol. 2020;17(3):253–63. https://doi.org/10.1111/ajco.13451.CrossRefPubMed

23.

Zhang Y, Zhang W. FOXD1, negatively regulated by miR-186, promotes the proliferation, metastasis and radioresistance of nasopharyngeal carcinoma cells. Cancer Biomark. 2020;28(4):511–21. https://doi.org/10.3233/CBM-191311.CrossRefPubMed

24.

Han T, Lin J, Wang Y, Fan Q, Sun H, Tao Y, et al. Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer. Biomed Pharmacother. 2018;103:1369–75. https://doi.org/10.1016/j.biopha.2018.04.190.CrossRefPubMed

25.

Lin CH, Lee HH, Chang WM, Lee FP, Chen LC, Lu LS, et al. FOXD1 Repression Potentiates Radiation Effectiveness by Downregulating G3BP2 Expression and Promoting the Activation of TXNIP-Related Pathways in Oral Cancer. Cancers (Basel). 2020;12(9). https://doi.org/10.3390/cancers12092690.

26.

Tao J, Cong H, Wang H, Zhang D, Liu C, Chu H, et al. MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1. Biochem Biophys Res Commun. 2018;503(2):1092–7. https://doi.org/10.1016/j.bbrc.2018.06.121.CrossRefPubMed

Title: Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC
Authors: Jin Li
Tingyuan Yan
Xiang Wu
Xueping Ke
Xin Li
Yumin Zhu
Jianrong Yang
Zhongwu Li
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08868-4

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study

Assessing service availability and readiness to manage cervical cancer in Bangladesh

Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients

LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p

Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis

Comparison of fatigue and fatigability correlates in Korean breast cancer survivors and differences in associations with anxiety, depression, sleep disturbance, and endocrine symptoms: a randomized controlled trial